Journal of Hematology Oncology Pharmacy

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Featured Articles

Original Article

Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors

Original Article

Assessment of the Elimination of Test Doses for Paclitaxel and Carboplatin in Patients with Cancer

Original Article

Outcomes and Adverse Events Linked to Off-Label Treatment of Solid Tumors with PARP Inhibitors

Review Article

Pancreatic Cancer: Review of the Current and Investigational Drug Landscape

Case Reports

Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report

Case Reports

The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor–Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature

Thank You JHOP Peer Reviewers

The Editors and Publisher of the Journal of Hematology Oncology Pharmacy (JHOP) wish to express their gratitude to the many hematology oncology pharmacists and other healthcare professionals who have contributed their expertise in the peer-review process...

CONTINUE READING

FDA Oncology Update

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer

Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation

Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma

Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma

Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer

Rylaze Received FDA Approval of a New Dosing Regimen

Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma

Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations

Most Popular Articles

August 2022 Clinical Trials to Clinical Practice - Clinical Trials, Melanoma

Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy

JHOP - October 2022 Vol 12, No 5 - Original Article

Time to First Palbociclib Prescription Dispense at Mayo Clinic: Comparing a Health-System Specialty Pharmacy with External Specialty Pharmacies

JHOP - October 2022 Vol 12, No 5 - Original Article

Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting

JHOP - October 2022 Vol 12, No 5 - Original Article

Evaluating Institutional Safety Standards Related to Continuing Oral Antineoplastic Medication Use During Hospitalization

JHOP - August 2022 Vol 12, No 4 - Original Article, Prostate Cancer, Genitourinary Cancers, Targeted Therapies

Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer

JHOP - October 2022 Vol 12, No 5 - Practical Issues in Pharmacy Management

Implementation and Evaluation of a Formal Investigational Drug Service at a Community Cancer Center

Copyright © The Lynx Group, LLC. All rights reserved.